Alternatives to standard blood transfusion: Availability and promise

Transfusion Medicine

Volumn 9, Issue 4, 1999, Pages 287-299

  Prowse, C V ^a  

^a SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

Author keywords

Blood; Haemoglobin; Plasma; Platelet; Protein; Recombinant; Substitute; Transgenic

Indexed keywords

BLOOD SUBSTITUTE; FLUOROCARBON;

ANIMAL; BLOOD CELL; BLOOD COMPONENT THERAPY; BLOOD TRANSFUSION; ECONOMICS; HUMAN; MICROBIOLOGY; REVIEW; STANDARD;

ANIMALS; BLOOD CELLS; BLOOD COMPONENT TRANSFUSION; BLOOD SUBSTITUTES; BLOOD TRANSFUSION; FLUOROCARBONS; HUMANS;

EID: 0033485362     PISSN: 09587578     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3148.1999.00212.x     Document Type: Review

References (92)

1. Ackerman, S., Edson, C., Purmal, A., Zang, Q.X. & Budowski, E. (1998) Inactine - a potent and selective method for inactivating viruses in contaminated blood products. Vox Sanguinis, 74 (Suppl. 1), 1305.
2. Allain, J.P. (1998) Update statement from the conference 'Autologous transfusion, 3 years on - what is new? what has happened?' held at the Royal College of Physicians of Edinburgh, 10-11 November. British Journal of Haematology, 104, 640.
3. Alving, A. (1998) Potential for synthetic phospholipids as partial platelet substitutes. Transfusion, 38, 997-998.
4. Amgen. (1999) Novel erythropoiesis stimulating protein, a hyperglycosylated epo with 3-fold longer half-life. International Blood Plasma News, January, 83.
5. Banchereau, J. (1997) Dendritic cells; therapeutic potential. Transfusion Science, 18, 313-326.
6. Ben-Hur, E., Chan, W.S., Zuh, M.M., Yim, Z., Roth, N., Heldman, E., Lazo, A. & Horowitz, B. (1999) Photochemical Decontamination of Red Blood Cell Concentrates with the Silicon Phthalocyanine Pc4 and Red Light. International Society Blood Transfusion, Meeting Abstract Jerusalem, May 1999, p. 80.
7. Bernstein, D.E., Jeffers, L., Erhardtsen, E., Reddy, K.R., Glazer, S., Squiban, P., Bech, R., Hedner, U. & Schiff, E.R. (1997) Recombinant factor Vila corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology, 113, 1930-1937.
8. Bianco, C. (1999) Choice of human plasma preparations for transfusion. Transfusion Medicine Reviews, 13, 84-88.
9. Blajchman, M.A. & Lee, D.H. (1997) The thrombocytopenic rabbit bleeding time model to evaluate the in vivo hemostatic properties of platelets and platelet substitutes. Transfusion Medicine Reviews, 11, 95-105.
10. Bode, A.P., Read, M.S. & Reddick, R.L. (1999) Activation and adherence of lyophilised human platelets on canine vessel strips in the Baumgartner perfusion chamber. Journal of Laboratory and Clinical Medicine, 133, 200-211.
11. Brenner, M.K., Heslop, H.E. & Rooney, C.M. (1998) Gene and cell transfer for specific immunotherapy. Vox Sanguinis, 74 (Suppl. 2), 87-90.
12. British Committee for Standards in Haematology. (1992) Guidelines for the use of fresh frozen plasma. Transfusion Medicine, 2, 57-63.
13. Brodniewicz, T. (1998) Review of clinical trials to date for major indications for fibrin sealant. Cambridge Healthcare Institute Conference, Lisbon, November 1998.
14. Campbell, K.H.S., McWhir, J., Ritchie, W.A. & Wilmut, I. (1996) Sheep cloned by nuclear transfer from a cultured cell line. Nature, 380, 64-66.
15. Chang, T.M.S. (1999) Blood substitutes. Principles, Methods, Products and Clinical Trials, Vols I and II. Karger-Landes Systems.
16. Chao, F.C., Kim, B.K., Houranieh, A.M., et al. (1996) Infusible platelet membrane microvesicles: a potential transfusion substitute for platelets. Transfusion, 36, 536-542.
17. Cochrane Injuries Group of Albumin Reviewers. (1998) Human albumin administration in critically ill patients, systemic review of controlled trials. British Medical Journal, 317, 235-240.
18. Cook, D., Merritt, J., Nerio, A., Rapaport, H., Stassinopoulous, A., Wollowitz, S. & Matejovic, J. (1998) (Cerus Corporation) Patent on Frangible Compounds for Pathogen Inactivation. WO98/30545.
19. Corash, L. (1999) Inactivation of viruses, bacteria, protozoa and leukocytes in platelet concentrates: current research perspectives. Transfusion Medicine Reviews, 14, 18-30.
20. Cottingham, I.R. (1998) Recombinant plasma proteins from transgenic animals. Transfusion Medicine, 8 (Suppl. 1), 3.
21. Currie, L.M., Lichtiger, B., Livesey, S.A., Tansey, W., Yang, D.J. & Connor, J. (1999) Enhanced circulatory parameters of human platelets cryopreserved with second-messanger effectors. an in vivo study of 16 volunteer platelet donors. British Journal of Haematology, 105, 826-831.
22. Cwirla, S.E., Balasubramanian, P., Duffin, D.J., Wagstrom, C.R., Gates, C.M., Singer, S.C., Davis, A.M., Tansik, R.L., Mattheakis, L.C., Boytos, C.M., Schatz, P.J., Baccanari, D.P., Wrighton, N.C., Barrett, R.W. & Dower, W.J. (1997) Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science, 276, 1696-1699.
23. Dale, D.C., Liles, W.C. & Price, T.H. (1997) Annotation. Renewed interest in granulocyte transfusion therapy. British Journal of Haematology, 98, 497-501.
24. Delgado, C., Francis, G.E. & Fisher, D. (1992) The uses and properties of PEG-linked proteins. Critical Reviews in Therapeutic Drug Carrier Systems, 9, 249-304.
25. Department of Health. (1998) Government accepts advice on leucodepletion from Spongiform Encephalopathy Advisory Committee. Press Release, 98/295, 17 July 1998.
26. Ellund, S. (1998) Manufacturing biopharmaceutical proteins using transgenic animals. Biopharma Europe, June 10-16.
27. Faithfull, N.S. & Weeks, J.G. (1998) Perfluorocarbons. Vox Sanguinis, 74 (Suppl. 2), 243-248.
28. FDA. (1999) Draft Guidance for Industry: For Platelet Testing and Evaluation of Platelet Substitutes Products (available at http://www.fda.gov.cber/guidelines/htm).
29. Fergusson, D., van Walraven, C., Coyle, D. & Laupacis, A. (1999) Economic evaluations of technologies to minimise peri-operative transfusion. A systemic review of published studies. Transfusion Medicine Reviews, 13, 106-117.
30. Gage, F.H. (1998) Cell therapy. Nature, 392, 18-24.
31. Gilliland, L.K., Walsh, L.A., Frewin, M.R., Wise, M.P., Tone, M., Hale, G., Kioussis, D. & Walkmann, H. (1999) Elimination of the immunogenicity of therapeutic antibodies. Journal of Immunology, 162, 3663-3771.
32. Goodnough, L.T., Brecher, M.E., Kanter, M.H. & AuBuchon, J.P. (1999) Transfusion medicine. First of two parts. Blood Transfusion. New England Journal of Medicine, 340, 438-447.
33. Gunthard, H.F., Gowland, P.L., Schupbach, J., Fung, M.S.C., Boni, J., Liou, R.S., Chang, N.T., Grob, P., Graepel, P., Braun, D.G. & Luthy, R. (1994) A phase I/IIa. clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120. Journal of Infectious Diseases, 170, 1384-1393.
34. Habler, O.P., Kleen, M.S., Hutter, J.W., Podtschaske, A.H., Tiede, M., Kemming, G.I., Welte, M.W., Corso, C.O., Batra, S., Keipert, P.E., Faithfull, N.S. & Messmer, K.F.W. (1998) Hemodilution and intravenous perflubron emulsion as an alternative to blood transfusion: effects on tissue oxygenation during profound hemodilution in anesthetized dogs. Transfusion, 38, 145-155.
35. Hamblin, T. (1997) Cytokines to reduce platelet transfusions. Non-TPO cytokines. Transfusion Science, 18, 121-128.
36. Horowitz, B., Bonomo, R., Prince, A.R.M., Chin, S.N., Brotman, B. & Schulman, R.W. (1992) Solvent-detergent treated plasma. a virus-inactivated substitute for fresh frozen plasma. Blood, 79, 826-831.
37. Horowitz, B. (1999) Progress Toward the Viral Inactivation of Blood Components: Cambridge Healthtech Institute meeting on Blood Safety, Virginia, February 1999.
38. Israel, E. & Simister, N. (1998) World patent on 'Modulation of IgG binding to FcRn' WO 98/23289.
39. Jackson, M.R., MacPhee, M.J., Drohan, W.N. & Alving, B.M. (1996) Fibrin sealant: current and potential clinical applications. Blood Coagulation and Fibrinolysis, 7, 737-746.
40. Johnson, S., Oliver, C., Prince, G.A., Hemming, V.G., Pfarr, D.S., Wang, S.C., Dormitzer, M., O'Grady, J., Koenig, S., Tamura, J.K., Woods, R., Bansal, G., Gouchenour, D., Tsae, E., Hall, W.C. & Young, J.F. (1997) Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. Journal of Infectious Diseases, 175, 1215-1224.
41. Kaushansky, K. (1995) Thrombopoietin. The Primary Regulator of Platelet Production. Blood, 86, 419-431.
42. Kruskall, M.S. & AuBuchon, J.P. (1997) Making Landsteiner's discovery superfluous: safety and economic implications of a universal group O red blood cell supply. Transfusion Science, 18, 613-620. (see also World patent WO98/21944).
43. 1 red blood cells and suppression of Rh D immunization in Rh D volunteers. Blood, 86, 1701-1709.
44. Kuter, D.J., Cebon, J., Harker, L.A., Petz, L.D. & McCullough, J. (1999) Platelet growth factors. Potential impact on transfusion medicine. Transfusion, 39, 321-332.
45. Lambrecht, B., Mohr, H., Knuever-Hope, J. & Schmitt, H. (1991) Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sanguinis, 60, 207-213.
46. Laupacis, A. & Fergusson, D. (1997) for the International Study of Perioperative Transfusion (ISPOT) Investigators. Drugs to minimise peri-operative blood loss in cardiac surgery - Meta analysis using peri-operative blood transfusions as the outcome. Anesthesia and Analgesia, 85, 1258-1267. (See also Transfusion Medicine, 1998, 8, 309-317.)
47. Laupacis, A. & Fergusson, D. (1997) for the International Study of Perioperative Transfusion (ISPOT) Investigators. Drugs to minimise peri-operative blood loss in cardiac surgery - Meta analysis using peri-operative blood transfusions as the outcome. Anesthesia and Analgesia, 85, 1258-1267. (See also Transfusion Medicine, 1998, 8, 309-317.)
48. Lee, D.H. & Blajchman, M.A. (1998) Novel platelet products and substitutes. Transfusion Medicine Reviews, 12, 175-187.
49. Levi, M., Friedrich, P.W., Middleton, S., de Groot, P.G., Wu, Y.P., Harris, R., Biemond, B.J., Heijnen, H.F.G., Levin, J. & ten Cate, J.W. (1999) Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Nature Medicine, 5, 107-111.
50. Lind, P., Larsson, K., Spira, J., Sydow-Backman, M., Almstedt, A., Gray, E. & Sandberg, H. (1995) Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization. European Journal of Biochemistry, 15, 232 (1): 19-27.
51. Linden, R.M. & Woo, S.L.C. (1999) AAVant-garde gene therapy. Nature Medicine, 5, 21-22.
52. Mannucci, P.M. (1997) DDAVP: twenty years after. Thrombosis and Haemostasis, 78, 958.
53. Martinowitz, U. & Spotnitz, W.D. (1997) Fibrin tissue adhesives. Thrombosis and Haemostasis, 78, 661-666.
54. Menys, V.C., Phipps, D.J., Grandage, L.M. & Roser, B.J. (1998) Patent on Methods and Compositions for Producing Dried Storage-Stable Platelets (assigned to Quadrant). WO98/34478.
55. Modi, N.B., Eppler, S., Breed, J., Cannon, C.P., Braunwald, E. & Love, T.W. (1998) Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. Thrombosis and Haemostasis, 79, 134-139.
56. Morrow, J.F., Braine, H.G., Kickler, T.S., Ness, R.M., Dick, J.D. & Fuller, A.K. (1991) Septic reactions to platelet transfusion: a persistent problem. Journal of the American Medical Association, 266, 555-558. (See also Blajchman, M.A. (1998) Transfusion associated sepsis. Vox Sanguinis, 74 (Suppl. 2), 155-159.)
57. Morrow, J.F., Braine, H.G., Kickler, T.S., Ness, R.M., Dick, J.D. & Fuller, A.K. (1991) Septic reactions to platelet transfusion: a persistent problem. Journal of the American Medical Association, 266, 555-558. (See also Blajchman, M.A. (1998) Transfusion associated sepsis. Vox Sanguinis, 74 (Suppl. 2), 155-159.)
58. Murad, K.L., Mahany, K.L., Kupyers, F.A., Brugnara, C., Eaton, J.W. & Scott, M.D. (1999) Structural and functional consequences of antigenic modulation of red cells with methoxypoly (ethylene glycol). Blood, 93, 2121-2127.
59. Norfolk, D.R. & Williamson, L. (1995) Leucodepletion of blood products by filtration. Blood Reviews, 99, 7-14.
60. Novo Nordisk. (1999) International Blood and Plasma News, April, 121.
61. Ogawa, M. & Matsunaga, T. (1999) Humoral regulation of hematopoietic stem cells. Annals of NY Academy of Science, 872, 17-24.
62. Pamphilon, D.H., Rider, J.R., Barbara, J.A.T. & Williamson, L.M. (1999) Prevention of transfusion-transmitted cytomegalovirus infection. Transfusion Medicine, 9, 115-124.
63. Peault, B. & Charbord, P. (1997) Gene transfer into human haematopoietic stem cells. Transfusion Science, 18, 291-311.
64. Piacibello, W., Sanano, F., Severina, A., Garetto, L., Dane, A., Gammastoni, L. & Aglietta, M. (1998) Ex. vivo expansion of cord blood progenitors. Vox Sanguinis, 74 (Suppl. 2), 457-462.
65. Prowse, C.V. (1994) Kill and cure: the hope and reality of virus inactivation. Vox Sanguinis, 67 (Suppl. 3), 191-196.
66. Raanani, P., Dazzi, F., Sohal, J., Szydlo, R.M., van Rhee, F., Reiter, A., Lin, F., Goldman, J.M. & Cross, N.C.P. (1997) The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. British Journal of Haematology, 99, 945-950.
67. Redecker-Klein, A. & Mohr, H. (1998) Thionine-light for virus inactivation of platelet concentrates. Vox Sanguinis, 74 (Suppl. 1), 1302.
68. Reid, T.J., Esteban, G., Clear, M. & Gorogias, M. (1999) Platelet membrane integrity during storage and activation. Transfusion, 39, 616-624.
69. Reuters. (1999) (Washington) Man Gets Experimental Gene Therapy for Hemophilia. June 3.
70. Rice, A., Ripoche, J. & Reiers, J. (1997) Hematopoietic stem cell expansion. Transfusion Science, 18, 263-275.
71. Rooney, C.M., Heslop, H.E. & Brenner, M.K. (1998) EBV specific CTL. a model for immune therapy. Vox Sanguinis, 74 (Suppl. 2), 497-498.
72. Royal College of Physicians of Edinburgh. (1999) Autologous transfusion - three years on. What is new? What has happened? Transfusion Medicine, 9, 285-286.
73. SCRIP. (1998) Antibody problems for Amgen's platelet growth factor. 21 August.
74. Serious Hazards of Transfusion Committee. (1999) SHOT annual report. (1997-98) Manchester.
75. Somlo, G., Sniecinski, I., ter Veer, A., Longmate, J., Knutson, G., Vuk-Pavlovic, S., Bhatia, R., Chow, W., Leong, L., Morgan, R., Margolin, K., Raschko, J., Shibata, S., Tetef, M., Yun, Y., Forman, S., Jones, D., Ashby, M., Fyfe, G., Hellmann, S. & Doroshow, J.H. (1999) Recombinant human thrombopoietin in combination with granulocyte colony stimulating factor enhances mobilisation of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates haematopoietic recovery following high dose chemotherapy. Blood, 93, 2798-2806.
76. Spivak, J.L. (1994) Recombinant human erythropoietin and its role in transfusion medicine. Transfusion, 34, 1-4.
77. Stokes, R. (1999) Commercialisation of 'Milked' Medicines. Biopharma Report, March, 58-59.
78. Thomas, E.D. (1999) A history of haemopoietic cell transplantation. British Journal of Haematology, 105, 330-339.
79. Turner, M.L. & Ironside, J.W. (1998) New-variant Creutzfeldt-Jakob disease: the risk of transmission by blood transfusion. Blood Reviews, 12, 255-268.
80. US patent 5,506,132. (1994) Human antibodies against Varicella zoster. Sandoz.
81. Velander, W.H., Lubon, H.K. & Drohan, W.N. (1997) Transgenic Livestock as Drug Factories. Scientific American, January, 70-74.
82. Vitex. (1999) Voluntary recall of PLAS+ SD. ABC Newsletter, 14 May, 9 (available on http://www.fda.gov/cber/ recalls.htm).
83. Voak, D., Caffrey, E.A., Barbara, J.A.J., Pollock, A., Scott, M. & Contreras, M.C. (1998) Affordable safety for the blood supply in developed and developing countries. Transfusion Medicine, 8, 73-76.
84. Wagner, S.J., Skripchenko, A., Ribinette, D., Mallory, D.A. & Cincotta, L. (1998) Preservation of red cell properties after virucidal treatment with dimethyl methylene blue. Transfusion, 38, 729-737.
85. Welte, K., Gabrilove, J., Bronchud, M.H., Platzer, E. & Morstyn, G. (1996) Filgrastin (r-mrtHuG-CSF). The first ten years. Blood, 88, 1907-1929.
86. World Health Organisation. (1998) Developing a national policy and guidelines on the clinical use of blood -Recommendations. Transfusion Today, December, 1998, 3-9.
87. World patent 94/11495. (1994) Production of human monoclonal antibodies specific for hepatitis B. Sandoz Ltd.
88. World patent WO 94/16730. (1994) Human monoclonal antibodies to cytomegalovirus. Sandoz Ltd.
89. World patent WO 97/129128. (1997) GPIb-Lipid Complex and uses thereof. Green Cross. (See also Toray Industries patent WO98/32771.)
90. Wrighton, N.C., Balasubramanian, P., Barbone, F.P., Kashyap, A.K., Farrell, F.X., Jolliffe, L.K., Barrett, R.W. & Dower, W.J. (1997) Increased potency of an erythropoietin peptide mimetic through covalent dimerization. Nature Biotechnology, 15, 1261-1265.
91. Yen, R. & Yorba, L. (1996) World patent on Protein Particles for Therapeutic and Diagnostic use: WO 96/39128.
92. Ziegler, B.L. & Kanz, L. (1998) Expansion of stem and progenitor cells. Current Opinions in Hematology, 5, 434-440.